1 million, as compared to $8.
General and administrative expense increased to $3.com . Such statements involve known and unknown risks,
uncertainties and other factors which may cause actual events to differ
materially from expectations.com.

lauver romanians

aureus bacteremia. 31,
2005 2004

ASSETS
Current assets:
Cash and cash equivalents $26,275,755 $71,580,823
Short-term investments 39,650,942 15,623,887
Prepaid expenses and other current assets 1,848,910 1,082 ,359
Accounts receivable 192,178 322,019
Total current assets 67,967,785 88,609,088
Property and equipment, net 7,649,820 2,629,987
Total assets $75,617,605 $91,239,075

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable $1,132,137 $3,077,636
Accrued expenses 5,330,195 3,587,093
Current portion of notes payable 1,409,466 877,239
Current portion of capital lease obligations 570 ,739 315,043
Current portion of deferred revenue 191,667 191,667
Other current liabilities 1,263,563 1,000,000
Total current liabilities 9,897,767 9,048,678
Long-term liabilities:
Notes payable , net of current portion 1,557,506 486,112
Capital lease obligations, net of
current portion 1,065,696 321,190
Deferred revenue, net of current portion 762,498 837,498
Other liabilities, net of current portion 1,388,018 -
Total long-term liabilities 4,773 ,718 1,644,800
Stockholders' equity:
Preferred stock, $.com

Now that these texts are available online,
researchers can easily search for specific names and events.com , Inc.

genealogies keyser

With respect to Aurexis, our second product candidate, we
achieved a number of important milestones during this past quarter, the most
notable of which was the announcement of favorable top line results from our
Phase II bacteremia clinical trial.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve
substantial risks and uncertainties.
(A DEVELOPMENT STAGE COMPANY)
CONDENSED BALANCE SHEETS
(unaudited)

June 30, Dec.

Study family trees submitted by genealogists
Many researchers assume their efforts are pioneering, but many
genealogists have already researched the exact same family lines.com. provides the largest and most popular collection of
online information for connecting families with their histories and with one
another.

deed greenlee

"Our second quarter results illustrate that we continued to be good fiscal
stewards of our capital resources while advancing our clinical programs on or
slightly ahead of schedule," stated William D.5 and $0.9 million, respectively, in additional
direct costs incurred in 2005 as a result of the Company becoming publicly-
traded in June 2004, including higher audit and legal fees, consulting fees
associated with implementing the requirements of Section 404 of the Sarbanes-
Oxley Act, increased board of directors' fees and increased premiums for
directors ' and officers' liability insurance.
Financial guidance involves a high level of uncertainty and is subject to
numerous assumptions and factors. Based on the results
of this trial, the Company intends to advance Aurexis into an appropriately-
powered, follow-on trial in this indication. To access the replay, please dial 888-
203-1112 (domestic) or 719-457-0820 (international), and reference the access
code 7074225.com. The
Company may not update these forward-looking statements, even though its
situation may change in the future, unless it has obligations under the
Federal securities laws to update and disclose material developments related
to previously disclosed information.

CONTACTS:
Inhibitex, Inc. Plumb
Chief Financial Officer
(678) 746 -1136
rplumb@inhibitex.com

Lilian Stern (Investors)
Stern Investor Relations , Inc. Many industries, such as retail, experience upwards
of 100% annual turnover.S."

About MyFamily.

colletta manifests

In addition, for the three
month and six month period ended June 30, 2005, personnel -related costs
increased by $0.
The Company completed its eight-patient Phase I clinical trial of Aurexis
to evaluate its safety and pharmacokinetics in patients with end-stage renal
disease (ESRD)., president and chief executive officer, and
other members of Inhibitex's senior management team will review second quarter
results and provide an update on the Company's clinical development programs
via a webcast and conference call today at 8:30 a. KMS understands the
complexities of today's business environment and how to help organizations
effectively use their corporate knowledge base to manage growth and
profitability. For more information, please visit our website at
http: //wwww.

Search the U. Federal Census
For many African-Americans, the paper trail begins with the 1870 Census.

Read slave narratives
Journals and slave narratives are among the most evocative of genealogical
resources for African-Americans.com to
conveniently share your family tree, pictures, and documents with family
members. The company's tools, content and community empower individuals to
find the people most important to them, and to discover and share their unique
family stories.

genealogist storbeck

"

Second Quarter 2005 Financial Results
At June 30, 2005 the Company held cash, cash equivalents and short-term
investments of $65. The
increase of $2.7 million in 2005 is largely the result of a $1.1 million for the same period in 2004.4 million and $0.

2005 Financial Guidance
The Company provided updated financial guidance, indicating it currently
anticipates that its financial results for the fiscal year ending December 31,
2005 should reflect the following:
* Total revenue of approximately $800,000 to $1. All statements, other than statements of
historical facts included in this press release, including statements
regarding: the expected to time to complete enrollment in its ongoing Phase
III clinical trial of Veronate; the Company's intention to proceed to an
appropriately-powered clinical trial of Aurexis in patients with documented S.com

Kathryn Morris (Media)
KMorrisPR
(845) 635-9828
kathryn@kmorrispr.40) $(1. "Our design goals were, therefore,
focused on developing a simple and elegant solution that insured accuracy and
completeness thus creating a positive experience for every new employee.
"Starting with our very first implementation at Randall's Food Markets ,
several years ago, and continuing through more recent engagements at Giant
Foods, Stop + Shop and Diamond Contract Services, we have continually seen the
need and clear value proposition provided by an electronic OnBoarding
process," added Robert Jordan, Principal of KMS. Such factors include the following (1)
technological, engineering, quality control or other circumstances which could
delay the sale or shipment of products containing the Company's technology;
(2) economic, business , market and competitive conditions in the software
industry and technological innovations which could affect the Company's
business; (3) the Company's inability to protect its trade secrets or other
proprietary rights, operate without infringing upon the proprietary rights of
others or prevent others from infringing on the proprietary rights of the
Company; and (4) general economic and business conditions and the availability
of sufficient financing.
Another great resource is the Census Free Population Schedules.

massechusetts genealogist

5 million in 2004.

Second Quarter Highlights and Recent Developments

* Veronate
With respect to its 2,000-patient Phase III trial of Veronate for the
prevention of hospital-associated infections in very low birth weight infants,
the Company indicated that it has qualified and initiated 95 sites, 91 of
which have enrolled at least one patient. The Company's business,
financial condition, results of operations, and prospects may change. CIC is headquartered in Redwood Shores, California and
has a joint venture, CICC, in Nanjing, China.kmanage . Gather the records you have on
hand and compare them with your outline. With more than 4 billion records
available online, MyFamily.

hearthstone electors

9 million.0 million
for the second quarter of last year.

7 million for the same period in 2004.

As compared to prior guidance provided by the Company , this updated
financial guidance reflects a slight increase in revenues, a $2 million
decrease in expected operating expenses for the year and a $4 million increase
in anticipated cash, cash equivalents and short-term investments on hand at
December 31, 2005. EDT on August 2, 2005
until 11:59 pm EDT on August 9, 2005. Given these uncertainties, you should not place undue reliance on these
forward -looking statements, which apply only as of the date of this press
release. The Company qualifies all of the
information contained in this press release, and particularly its forward-
looking statements, by these cautionary statements.001 par value; 75,000,000
shares authorized at June 30, 2005 and
December 31, 2004; 25,203,583 and 25,133,327
shares issued and outstanding at June 30,
2005 and December 31, 2004, respectively 25,204 25 ,133
Common stock warrants 11,555,968 11,555,968
Additional paid-in capital 173,353,502 173,188,745
Deferred stock compensation (1,020,723) (1,269,099)
Deficit accumulated during the
development stage (122,967,381)(102,955,150)
Total stockholders' equity 60,946,120 80,545,597
Total liabilities and
stockholders ' equity $75,617,605 $91,239,075

INHIBITEX , INC.
(A DEVELOPMENT STAGE COMPANY)
CONDENSED STATEMENTS OF OPERATIONS
(unaudited)

Three Months Ended Six Months Ended
June 30, June 30,
2005 2004 2005 2004
Revenue:
License fees and
milestones $37,500 $37,500 $75,000 $75 ,000
Collaborative research
and development 125,000 125,000 250,000 250,000
Grants and other
revenue 6,020 - 120,651 -
Total revenue 168,520 162,500 445,651 325 ,000
Operating expense:
Research and
development 8,781,635 6,061,771 17,911,248 10,099,756
General and
administrative 1,799,041 818,937 3,207,456 1,661,448
Amortization of
deferred stock
compensation 124,188 118,193 248,376 224,913
Total operating
expense 10,704,864 6,998,901 21,367,080 11,986,117

Loss from
operations (10,536,344) (6,836,401) (20,921,429) (11,661,117)
Other income
(expense), net - - - 14,050
Interest income
(expense ), net 466,351 10,255 908,748 13,403
Net loss (10,069,993 ) (6,812,096) (20,012,681) (11,633,664)

Dividends and
accretion to
redemption value
of redeemable
preferred stock - (1,221,822) - (2 ,823,160)
Net loss
attributable
to common
stockholders $(10 ,069,993) $(8,033,918) $(20,012,681) $(14,456,824)

Basic and diluted
net loss per share
attributable to
common stockholders $(0. With SignatureOne, even documents containing multiple
eSignatures, such as employee and managing supervisor, each utilizing a
different signing method, result in a consistent set of data collected and
preserved with each signing."
XpressHR increases Sarbanes-Oxley compliance through documented repeatable
HR process and virtually eliminates direct and indirect labor expense
associated with new employee processing, duplicate data entry and photocopies. All other
trademarks and registered trademarks are the property of their respective
holders. The company also
publishes Family Tree Maker(R), the #1 selling family tree software, Ancestry
Magazine, Genealogical Computing Magazine, over 50 book titles, and numerous
databases on CD-ROM.

genealogist burritt

D.0 million, as compared to
$14. This increase was a result of shares issued in
connection with the Company's initial public offering in June 2004, including
the conversion of all its preferred stock, and accrued dividends thereon, into
common stock upon the closing of that offering, and shares issued in
connection with a $50 million private placement (PIPE) financing that the
Company completed in November 2004.
Revenue in the second quarter of 2005 was $169,000 as compared to $163,000
in the second quarter of 2004.8 million resulted primarily from a $4. EDT. An archived webcast will
be available on the Inhibitex website approximately two hours after the event
for a period of thirty (30) days.
There may be events in the future that the Company is unable to predict
accurately , or over which it has no control.80) $(5. Equipped with the ability to sign
documents with any chosen eSignature method, XpressHR seamlessly interfaces
with virtually any applicant tracking and screening solution, eliminating the
paper, lengthy cycle times and related errors associated with on-boarding new
employees.com .

sytem genealogist

, president and
chief executive officer of Inhibitex .1 million during the second quarter of 2004.
In addition, it enables organizations to minimize the time invested in
administrative HR activities by streamlining and automating the HR process and
facilitating strategic decision making capabilities. SignatureOne and C-Token are trademarks of CIC.

Contact Information
CIC Knowledge Management Systems
Investor Relations Inquiries: KMS
Chantal Eshghipour Anita Coleman
650-802-7740 323-935-5300
rjordan@kmanage . MyFamily. MyFamily.

Share and Preserve
Show off your handiwork through a tangible heirloom to pass on to children
and grandchildren.

borderlands bellum

For the six months ended June 30, 2005,
net loss attributable to common stockholders was $20. To access the call,
please dial 800-475-3716 (domestic) or 719-457-2728 (international) five
minutes prior to the start time, and provide the access code 7074225. The Company's three preclinical programs include a collaboration
and joint development agreement with Dyax to develop fully human monoclonal
antibodies against MSCRAMM proteins on enterococci and a partnership with
Wyeth to develop staphylococcal vaccines.

Knowledge Management Systems Licenses CIC's SignatureOne Platform Delivering Paperless HR Onboarding Applications

About CIC
Communication Intelligence Corporation ("CIC") is the leading supplier of
biometric signature verification and a leading supplier of electronic
signature solutions and natural input software focused on emerging, high
potential applications including eTransactions, paperless workflow, handheld
computers and smartphones enabling the world with "The Power to Sign
Online(R)". Industry leaders such as
Charles Schwab, Fujitsu, IBM, Oracle, PalmSource, Prudential, Siebel Systems,
Siemens Medical Systems, Sony Ericsson, Symbol and TVA have licensed the
company's technology.S. Records of African-Americans Easily
Accessible Online

PROVO, Utah , Although African-Americans face more
challenges than almost any other ethnic group when it comes to tracing their
roots, online records can make the discovery of family history easier than
ever before. Census that listed former slaves as citizens and may
also include the last-known residences of their earliest free ancestors. By
reviewing family trees created by other genealogists, you might find
references to your own ancestors. The entire Slave
Narrative collection is available online through MyFamily.com, Inc.

massechusetts lauver

9 million for the six
months ended June 30, 2005 from $10.
Favorable results were observed in the composite primary endpoint of
mortality, relapse rate and infection -related complications, and a number of
secondary endpoints and ad-hoc analyses, including the progression in the
severity of sepsis, the number of days in the intensive care unit, and the
resolution of complications due to S.D.m.
(212) 362-1200
lilian@sternir.S.
CIC's SignatureOne (TM) eSignature Platform includes Sign-it(R), iSign(R) and
its companion Biometric eSignature Verification Server.com is making it easier everyday to discover who
you are and where you come from.

sytem prodividing

Inhibitex Inc. Reports Second Quarter 2005 Financial Results

40 for the second quarter of 2005, as compared to $1. For the six months ended June 30, 2005,
revenue was $446,000 as compared to $325,000 for the same period in 2004.8 million for the second quarter of 2004.5 million, respectively, as compared to the
same periods in 2004 primarily due to higher salaries, the hiring of
additional personnel , and recruiting and relocation expenses related to the
addition of a sales and marketing executive .inhibitex.com. The number of documents that must be completed and signed
by every new hire creates potential confusion, errors, oversights and delays,"
commented Yolanda Parker, Principal of KMS.

S.
"Fortunately, there is a vast collection of data available online that can
provide insight into your family history.

Sites where the primary focus is the selling of books about genealogy.

bellum prodividing

Enrollment in Veronate Phase III Trial Surpasses 1,500 Patients;
Company Improves Year-End Financial Guidance

ATLANTA, Inhibitex, Inc. (Nasdaq: INHX)
today announced its financial results for the second quarter ended June 30,
2005 and provided an update to its financial guidance related to the Company's
2005 fiscal year-end results."
Dr.
Basic and diluted net loss per share attributable to common stockholders
was $0.0 million;
* Total operating expenses of approximately $45 to $47 million; and
* Cash, cash equivalents and short-term investments in the amount of
approximately $39 to $41 million at December 31, 2005. These factors include , but are not limited
to, the variability, timing and costs associated with conducting clinical
trials , the enrollment rates in such trials, the results of these clinical
trials, the timing of the manufacturing of the related clinical trial
materials, the funding requirements of preclinical research programs , the cost
of filing, prosecuting and enforcing patents or other intellectual property
rights, the level of general and administrative expenses needed to support the
Company's business strategy and the potential that the Company may enter into
new licensing agreements or strategic collaborations in the future. A
replay of the call will be available from 11:30 a.

About Inhibitex
Inhibitex, Inc.
Russell H.72) $(0.

About Knowledge Management Systems
Knowledge Management Systems is a full service business process automation
firm specializing in deploying document management, electronic forms and
workflow automation technology to reduce expenses and improve operating
efficiency in paper-intensive functional areas such as human resources,
accounts payable and supply chain management.

Technology Helps African-Americans Discover Their Roots and Honor Black History Month

Census records are available online at
Ancestry. The MyFamily network of web-based products includes
MyFamily.

colletta greenlee

Johnston added, "Our Phase III clinical trial for Veronate for the
prevention of hospital-associated infections in premature, very low birth
weight infants continues to enroll well, which we believe is indicative of the
strong support among neonatologists to find a solution for this significant
unmet medical need.72 for the second
quarter of 2004.

Research and development expense for the second quarter of 2005 was $8.
The increase of $7 .2 million for the six
months ended June 30, 2005 from $1. The DSMB met and reviewed
available data after both 500 and 1,000 patients had been enrolled in the
trial, and in each case, unanimously agreed that the trial should continue as
designed, without modification. aureus bloodstream infections in hospitalized patients.com

INHIBITEX, INC. and BEVERLY HILLS , Calif., Communication Intelligence Corporation ("CIC")
(OTC Bulletin Board: CICI), the leading supplier of biometric signature
verification and a leading supplier of electronic signature solutions and
Knowledge Management Systems ("KMS"), a leader in providing solutions to
streamline manual and paper-intensive business processes, announced today a
licensing agreement for CIC's SignatureOne (TM) eSignature Platform and
components. "Embedding SignatureOne's
platform and components allows each XpressHR customer to pick and choose the
best signing method for each situation while insuring the maximum in security,
integrity and compliance. For more information, please
visit our website at http://www. KMS has provided extensive research, design, and
implementation services for a wide variety of Fortune 500 corporations,
financial institutions, government agencies and educational institutions.

Forward Looking Statement
Certain statements contained in this press release, including without
limitation, statements containing the words "believes", "anticipates" ,
"hopes", "intends", "expects", and other words of similar import, constitute
"forward looking " statements within the meaning of the Private Litigation
Reform Act of 1995.

keyser storbeck

The Company reported that its net loss attributable to common stockholders
for the second quarter of 2005 was $10.
Research and development expense increased to $17.
In June, the Company initiated a 30-patient , Phase II clinical trial of
Aurexis in patients with cystic fibrosis who are chronically colonized with S. Johnston, Ph. MyFamily.

wiard lauver

"Based upon our year-to-date financial
results, we now anticipate that we will burn less cash this year than we
initially expected, while not sacrificing the timely achievement of any of our
key clinical or regulatory milestones.6 million increase in expenditures related
to manufacturing of clinical trial material, of which the majority was
associated with the Aurexis program.
aureus. Two doses of Aurexis are being tested for safety, pharmacokinetics ,
and to evaluate the potential impact of Aurexis on S. KMS Is the First Partner to Embed CIC's SignatureOne(TM) to Automate HR
Application

REDWOOD SHORES , Calif. Once the employee
has completed and digitally signed the new hire packet, XpressHR
electronically routes the new hire information to all back office systems and
then automatically notifies all internal and external stakeholders. Birth certificates, marriage
licenses, and death records can provide much of the information you are
missing.

genealogies electors

The
increase in revenue in 2005 was the result of proceeds received from research
activities performed under a materials transfer agreement that did not exist
in 2004., headquartered in Alpharetta, Georgia, is a
biopharmaceutical company focused on the discovery, development and
commercialization of antibody-based products for the prevention and treatment
of serious, life-threatening infections.
"The New Hire or 'OnBoarding' process touches every employee regardless of
their job position.com, Genealogy.

lauver genealogist

We foresee completing full enrollment around the end of
November 2005. We plan to meet with the FDA this fall to
discuss our Phase II findings and the design of our follow-on trial for
Aurexis in this indication.80 as compared
to $5. aureus bacterial load
and pulmonary inflammation in these patients.m.
Inhibitex(R), MSCRAMM (R), Veronate(R), and Aurexis(R) are registered
trademarks of Inhibitex, Inc.001 par value; 5,000 ,000
shares authorized at June 30, 2005 and
December 31, 2004; none issued and outstanding - -
Common stock, $.
Under the terms of the agreement , KMS will embed CIC's patented
SignatureOne eSignature framework, methodology and process control components
into KMS' "XpressHR(TM)" application, thereby delivering a full range of
eSignature methods such as "click to sign," biometric handwritten eSignatures,
fingerprint and voice capture eSignatures. While much progress has been made on automated
recruiting systems, OnBoarding remains , for the most part, a paper based
process.
"We are pleased to partner with KMS bringing the significant benefits of
eSignature technology to the OnBoarding process," stated Guido DiGregorio ,
CIC's Chairman + CEO. Our
services range from concept development and full project management to overall
systems implementation.

manifests massechusetts

The increase in the loss in 2005 was principally due
to an increase in research and development expenditures and to a lesser
extent, an increase in general and administrative expenses, offset in part by
an increase in interest income and the elimination of non-cash charges
associated with dividends and accretion to redemption value of redeemable
preferred stock that was converted into common stock upon completion of the
Company's initial public offering in June 2004. The
increase for the three month and six month periods ended June 30, 2005, was
primarily the result of $0.inhibitex.
This is the first U. And many of these accounts contain insights into slave
folklore, poetry, songs, recipes and even ghost stories.com.
MyFamily.

sytem bellum

For the six months ended June 30, 2005, basic and diluted
net loss per share attributable to common stockholders was $0.7 million increase
in clinical costs, all of which were associated with the Company's ongoing
Phase III Veronate trial, and a $2.8 million in the second
quarter of 2005 as compared to $0.
A live audio webcast of the call will also be available on the "Investors"
section of the Company 's website, http://www. For additional information about
the Company, please visit http://www."
The XpressHR user interface allows each New Hire to complete the entire
new packet via the Internet in advance of their start date. Bureau of Labor and Statistics predicts more than 56,892,000 new
employees will be hired over the next twelve months in the US alone. "As a leader in broadly horizontal markets , KMS has
demonstrated that they know how to best leverage SignatureOne's robust and
flexible features into delivering unique and compelling value to their
customer base. More
importantly, these first -hand accounts not only provide a snapshot view of
slave life in America, but also sometimes provide details about a slave's
parents and/or owners.com.

borderlands romanians

Johnston, Ph.49 for the same period of 2004.8
million, as compared to $6.9 million
increase in clinical trial costs, virtually all of which was associated with
the Company's ongoing Phase III Veronate clinical trial, and to a lesser
extent , a $0.

* Aurexis
In May 2005, the Company reported top line results from its 60-patient
Phase II trial of Aurexis, in combination with antibiotics, for the treatment
of documented S .

Conference Call and Webcast Information
William D. Consider creating a website through MyFamily.

hearthstone sytem

5 million increase in expenditures related to manufacturing
clinical trial material for the Aurexis program.
Regardless of the method used to sign each document, all SignatureOne
eSignatures result in CIC's patented C-Token(TM) which contains all necessary
information to prove, substantiate , audit and enforce each signature within
each transaction. Recent
studies suggest the aggregated costs per each OnBoarding experience range from
$250 - $500 per employee.

NOTE: CIC, its logo and the Power to Sign Online are registered
trademarks.com Makes the Oldest Known U. Glancing at a
census record can reveal information like an ancestor's occupation, annual
income and home ownership.

voyagers colletta

The Company also reported that, as of July 31,
2005, it had enrolled more than 1,500 patients in a Phase III clinical trial
of its lead product candidate, Veronate. The significant reduction in net loss
per share attributable to common stockholders for both the three-month and six
month periods ended June 30, 2005, as compared to similar periods in 2004, was
due to a substantial increase in the number of weighted-average shares of
common stock outstanding. Based on the pharmacokinetic data from this trial, the
Company intends to include patients with ESRD in its follow-on trial of
Aurexis for the treatment of documented S. aureus bloodstream infections in
hospitalized patients .49)

Weighted average
shares used to
compute basic and
net loss per share
attributable
to common
stockholders 25,198,094 4,669,950 25,172,976 2,633,918

"
The U. CIC sells directly to
Enterprises, integration /channel partners and OEMs.cic.com, the most popular and comprehensive family history
research and connection resource online, offers the following tips to make the
search a bit easier:

Sketch your family tree based entirely on memory
Even if it's full of question marks, a rough draft will tell you what
you'll need to research in the coming months.com hosts the largest collection
of family trees on the Internet containing more than 250 million names.com, Ancestry.

cdroms burritt

General and administrative expense increased to $1. The Company also indicated that it
has now enrolled over 1,500 patients and therefore anticipates that the
independent Data Safety Monitoring Board (DSMB) responsible for evaluating
certain safety and statistical data from this trial will meet within the next
four to eight weeks to perform its third review. The Company currently has five drug
development programs, all of which are based on its proprietary MSCRAMM
protein platform technology. The Company 's most advanced product candidates
are Veronate and Aurexis, both of which the Company has retained worldwide
rights to.
aureus bloodstream infections; the Company's intention to meet in the fall
with the FDA to discuss the Aurexis; clinical development plan and guidance
regarding estimated revenues, expenses and cash balances for the fiscal year
ending December 31, 2005 are forward-looking statements. These plans,
intentions, expectations or estimates may not actually be achieved and various
important factors could cause actual results or events to differ materially
from the forward -looking statements that the Company makes, including risks
related to: the cost and time for investigators to enroll patients in the
Company's ongoing clinical trials; the use of third-party contract clinical
research organizations, raw material suppliers and manufacturers, who may not
fulfill their contractual obligations or otherwise perform satisfactorily in
the future; maintaining sufficient quantities of clinical trial materials on
hand to complete its clinical trials; the ability to obtain DSMB or regulatory
approval to commence or continue its clinical trials on a timely basis; the
length of time it takes the Company to perform a final evaluation of the Phase
II Aurexis data and unknown findings that may arise in the Company's final
analysis of such data; obtaining, maintaining and protecting the intellectual
property incorporated into and supporting its product candidates; maintaining
expenses, revenues and other cash expenditures substantially in line with
planned or anticipated amounts; the ability to obtain additional funding to
support its business activities and other cautionary statements contained
elsewhere herein, in its Annual Report on Form 10-K for the year ended
December 31, 2004 and in risk factors described in or referred to in greater
detail in the "Risk Factors" section of the Company's prospectus, which forms
part of its Registration Statement on Form S-3, which, as amended, was
declared effective by the Securities and Exchange Commission or SEC on July 7,
2005. CIC's products are designed to increase the ease of use,
functionality, and security of eBusiness processes and smart handheld devices. These
schedules list the names of African-American citizens living in the northern
free states prior to the Emancipation Proclamation of 1863.

"For African-Americans, piecing together family history can present some
unique challenges," said Tom Stockham, president and CEO of MyFamily.com, and RootsWeb.